R
5.37
-0.01 (-0.19%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Replimune Group, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.3
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.51% |
| 机构持股比例 | 107.50% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Boxer Capital Management, Llc | 30 Jun 2025 | 2,211,341 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 22.00 (HC Wainwright & Co., 309.68%) | 购买 |
| 中 | 4.00 (-25.51%) | |
| 低 | 2.00 (BMO Capital, -62.76%) | 卖出 |
| 平均值 | 7.00 (30.35%) | |
| 总计 | 2 购买, 4 保留, 1 卖出 | |
| 平均价格@调整类型 | 3.90 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BMO Capital | 23 Jul 2025 | 2.00 (-62.76%) | 卖出 | 3.34 |
| Barclays | 23 Jul 2025 | 3.00 (-44.13%) | 保留 | 3.34 |
| JP Morgan | 22 Jul 2025 | 9.00 (67.60%) | 保留 | 2.81 |
| 16 Jul 2025 | 19.00 (253.82%) | 购买 | 12.63 | |
| Jefferies | 22 Jul 2025 | 6.00 (11.73%) | 购买 | 2.81 |
| Leerink Partners | 22 Jul 2025 | 3.00 (-44.13%) | 保留 | 2.81 |
| Wedbush | 22 Jul 2025 | 4.00 (-25.51%) | 保留 | 2.81 |
| HC Wainwright & Co. | 03 Jul 2025 | 22.00 (309.68%) | 购买 | 9.40 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合